Advertisement

Index by author

December 01, 1985; Volume 28,Issue 6

A

  1. Abrass, I B

    1. Desensitization and resensitization of beta-adrenergic receptors in a smooth muscle cell line.
      P J Scarpace, L A Baresi, D A Sanford and I B Abrass
      Molecular Pharmacology December 1985, 28 (6) 495-501;

  2. Akaike, A

    1. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;

  3. Albuquerque, E X

    1. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;

  4. Aracava, Y

    1. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;

  5. Autry, W L

    1. Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its degradation in mouse brain.
      J A Norman, W L Autry and B S Barbaz
      Molecular Pharmacology December 1985, 28 (6) 521-526;

  6. Ayusawa, D

    1. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
      J Balzarini, E De Clercq, A Verbruggen, D Ayusawa and T Seno
      Molecular Pharmacology December 1985, 28 (6) 581-587;

B

  1. Balzarini, J

    1. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
      J Balzarini, E De Clercq, A Verbruggen, D Ayusawa and T Seno
      Molecular Pharmacology December 1985, 28 (6) 581-587;

  2. Barbaz, B S

    1. Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its degradation in mouse brain.
      J A Norman, W L Autry and B S Barbaz
      Molecular Pharmacology December 1985, 28 (6) 521-526;

  3. Baresi, L A

    1. Desensitization and resensitization of beta-adrenergic receptors in a smooth muscle cell line.
      P J Scarpace, L A Baresi, D A Sanford and I B Abrass
      Molecular Pharmacology December 1985, 28 (6) 495-501;

  4. Barovsky, K

    1. Forskolin potentiation of cholera toxin-stimulated cyclic AMP accumulation in intact C6-2B cells. Evidence for enhanced Gs-C coupling.
      K Barovsky and G Brooker
      Molecular Pharmacology December 1985, 28 (6) 502-507;

  5. Battaglia, G

    1. [3H]WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain. Guanine nucleotide and divalent cation sensitivity.
      A B Norman, G Battaglia and I Creese
      Molecular Pharmacology December 1985, 28 (6) 487-494;

  6. Blumer, J L

    1. Relationship between the oxidation potential of benzene metabolites and their inhibitory effect on DNA synthesis in L5178YS cells.
      P Pellack-Walker, J K Walker, H H Evans and J L Blumer
      Molecular Pharmacology December 1985, 28 (6) 560-566;

  7. Borgeat, P

    1. Stimulation of lipoxygenase product synthesis in human leukocytes and platelets by melittin.
      H Salari, P Braquet and P Borgeat
      Molecular Pharmacology December 1985, 28 (6) 546-548;

  8. Braquet, P

    1. Stimulation of lipoxygenase product synthesis in human leukocytes and platelets by melittin.
      H Salari, P Braquet and P Borgeat
      Molecular Pharmacology December 1985, 28 (6) 546-548;

  9. Bräutigam, M

    1. Effects of apomorphine enantiomers and of lisuride on 3,4-dihydroxyphenylalanine production in striatal synaptosomes.
      M Bräutigam, B Kittner and G Laschinski
      Molecular Pharmacology December 1985, 28 (6) 515-520;

  10. Brimijoin, S

    1. An inhibitory monoclonal antibody to rabbit brain acetylcholinesterase. Studies on interaction with the enzyme.
      S Brimijoin, K P Mintz and F G Prendergast
      Molecular Pharmacology December 1985, 28 (6) 539-545;

  11. Brooker, G

    1. Forskolin potentiation of cholera toxin-stimulated cyclic AMP accumulation in intact C6-2B cells. Evidence for enhanced Gs-C coupling.
      K Barovsky and G Brooker
      Molecular Pharmacology December 1985, 28 (6) 502-507;

  12. Bürgisser, E

    1. Activation of human blood platelets by arginine-vasopressin. Role of bivalent cations.
      A Pletscher, P Erne, E Bürgisser and F Ferracin
      Molecular Pharmacology December 1985, 28 (6) 508-514;

C

  1. Creese, I

    1. [3H]WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain. Guanine nucleotide and divalent cation sensitivity.
      A B Norman, G Battaglia and I Creese
      Molecular Pharmacology December 1985, 28 (6) 487-494;

D

  1. Daly, J W

    1. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;

  2. De Clercq, E

    1. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
      J Balzarini, E De Clercq, A Verbruggen, D Ayusawa and T Seno
      Molecular Pharmacology December 1985, 28 (6) 581-587;

E

  1. Erne, P

    1. Activation of human blood platelets by arginine-vasopressin. Role of bivalent cations.
      A Pletscher, P Erne, E Bürgisser and F Ferracin
      Molecular Pharmacology December 1985, 28 (6) 508-514;

  2. Evans, H H

    1. Relationship between the oxidation potential of benzene metabolites and their inhibitory effect on DNA synthesis in L5178YS cells.
      P Pellack-Walker, J K Walker, H H Evans and J L Blumer
      Molecular Pharmacology December 1985, 28 (6) 560-566;

F

  1. Ferracin, F

    1. Activation of human blood platelets by arginine-vasopressin. Role of bivalent cations.
      A Pletscher, P Erne, E Bürgisser and F Ferracin
      Molecular Pharmacology December 1985, 28 (6) 508-514;

G

  1. Giedroc, D P

    1. Binding of a synthetic beta-endorphin peptide to calmodulin.
      D P Giedroc and D Puett
      Molecular Pharmacology December 1985, 28 (6) 588-593;

H

  1. Handwerger, S

    1. Arachidonic acid stimulates phosphoinositide hydrolysis and human placental lactogen release in an enriched fraction of placental cells.
      P Zeitler and S Handwerger
      Molecular Pharmacology December 1985, 28 (6) 549-554;

K

  1. Kittner, B

    1. Effects of apomorphine enantiomers and of lisuride on 3,4-dihydroxyphenylalanine production in striatal synaptosomes.
      M Bräutigam, B Kittner and G Laschinski
      Molecular Pharmacology December 1985, 28 (6) 515-520;

L

  1. Laschinski, G

    1. Effects of apomorphine enantiomers and of lisuride on 3,4-dihydroxyphenylalanine production in striatal synaptosomes.
      M Bräutigam, B Kittner and G Laschinski
      Molecular Pharmacology December 1985, 28 (6) 515-520;

  2. Laufen, H

    1. The reaction between organic nitrates and sulfhydryl compounds. A possible model system for the activation of organic nitrates.
      R A Yeates, H Laufen and M Leitold
      Molecular Pharmacology December 1985, 28 (6) 555-559;

  3. Leitold, M

    1. The reaction between organic nitrates and sulfhydryl compounds. A possible model system for the activation of organic nitrates.
      R A Yeates, H Laufen and M Leitold
      Molecular Pharmacology December 1985, 28 (6) 555-559;

M

  1. Malick, N C

    1. Effects of hydroxyurea and thymidine derivatives on the uptake and metabolism of deoxycytidine and arabinofuranosylcytosine in log phase and contact-inhibited human diploid fibroblasts.
      R D Snyder and N C Malick
      Molecular Pharmacology December 1985, 28 (6) 574-580;

  2. Mintz, K P

    1. An inhibitory monoclonal antibody to rabbit brain acetylcholinesterase. Studies on interaction with the enzyme.
      S Brimijoin, K P Mintz and F G Prendergast
      Molecular Pharmacology December 1985, 28 (6) 539-545;

N

  1. Norman, A B

    1. [3H]WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain. Guanine nucleotide and divalent cation sensitivity.
      A B Norman, G Battaglia and I Creese
      Molecular Pharmacology December 1985, 28 (6) 487-494;

  2. Norman, J A

    1. Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its degradation in mouse brain.
      J A Norman, W L Autry and B S Barbaz
      Molecular Pharmacology December 1985, 28 (6) 521-526;

P

  1. Pellack-Walker, P

    1. Relationship between the oxidation potential of benzene metabolites and their inhibitory effect on DNA synthesis in L5178YS cells.
      P Pellack-Walker, J K Walker, H H Evans and J L Blumer
      Molecular Pharmacology December 1985, 28 (6) 560-566;

  2. Pletscher, A

    1. Activation of human blood platelets by arginine-vasopressin. Role of bivalent cations.
      A Pletscher, P Erne, E Bürgisser and F Ferracin
      Molecular Pharmacology December 1985, 28 (6) 508-514;

  3. Prendergast, F G

    1. An inhibitory monoclonal antibody to rabbit brain acetylcholinesterase. Studies on interaction with the enzyme.
      S Brimijoin, K P Mintz and F G Prendergast
      Molecular Pharmacology December 1985, 28 (6) 539-545;

  4. Puett, D

    1. Binding of a synthetic beta-endorphin peptide to calmodulin.
      D P Giedroc and D Puett
      Molecular Pharmacology December 1985, 28 (6) 588-593;

R

  1. Rickett, D L

    1. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;

S

  1. Salari, H

    1. Stimulation of lipoxygenase product synthesis in human leukocytes and platelets by melittin.
      H Salari, P Braquet and P Borgeat
      Molecular Pharmacology December 1985, 28 (6) 546-548;

  2. Sanford, D A

    1. Desensitization and resensitization of beta-adrenergic receptors in a smooth muscle cell line.
      P J Scarpace, L A Baresi, D A Sanford and I B Abrass
      Molecular Pharmacology December 1985, 28 (6) 495-501;

  3. Sartorelli, A C

    1. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
      J A Sokoloski and A C Sartorelli
      Molecular Pharmacology December 1985, 28 (6) 567-573;

  4. Scarpace, P J

    1. Desensitization and resensitization of beta-adrenergic receptors in a smooth muscle cell line.
      P J Scarpace, L A Baresi, D A Sanford and I B Abrass
      Molecular Pharmacology December 1985, 28 (6) 495-501;

  5. Seno, T

    1. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
      J Balzarini, E De Clercq, A Verbruggen, D Ayusawa and T Seno
      Molecular Pharmacology December 1985, 28 (6) 581-587;

  6. Shaw, K P

    1. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;

  7. Snyder, R D

    1. Effects of hydroxyurea and thymidine derivatives on the uptake and metabolism of deoxycytidine and arabinofuranosylcytosine in log phase and contact-inhibited human diploid fibroblasts.
      R D Snyder and N C Malick
      Molecular Pharmacology December 1985, 28 (6) 574-580;

  8. Sokoloski, J A

    1. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
      J A Sokoloski and A C Sartorelli
      Molecular Pharmacology December 1985, 28 (6) 567-573;

V

  1. Verbruggen, A

    1. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
      J Balzarini, E De Clercq, A Verbruggen, D Ayusawa and T Seno
      Molecular Pharmacology December 1985, 28 (6) 581-587;

W

  1. Walker, J K

    1. Relationship between the oxidation potential of benzene metabolites and their inhibitory effect on DNA synthesis in L5178YS cells.
      P Pellack-Walker, J K Walker, H H Evans and J L Blumer
      Molecular Pharmacology December 1985, 28 (6) 560-566;

Y

  1. Yeates, R A

    1. The reaction between organic nitrates and sulfhydryl compounds. A possible model system for the activation of organic nitrates.
      R A Yeates, H Laufen and M Leitold
      Molecular Pharmacology December 1985, 28 (6) 555-559;

Z

  1. Zeitler, P

    1. Arachidonic acid stimulates phosphoinositide hydrolysis and human placental lactogen release in an enriched fraction of placental cells.
      P Zeitler and S Handwerger
      Molecular Pharmacology December 1985, 28 (6) 549-554;
Back to top

In this issue

Advertisement